卵清蛋白纳米结构脂质载体的制备及理化性质的研究
Study on the preparation and physicochemical properties of ovalbumin-loaded nanostructured lipid carrier
作者：喻姣;孙逊;
Author：
收稿日期： 年卷（期）页码：2018,33(01):-20-23
期刊名称：华西药学杂志
Journal Name：WEST CHINA JOURNAL OF PHARMACEUTICAL SCIENCES
关键字：卵清蛋白;纳米结构脂质载体;复乳法;体外释放;细胞摄取;单因素实验;超滤法;理化性质
Key words：
基金项目：
中文摘要
目的制备并优化卵清蛋白纳米结构脂质载体(Ova-NLC)的处方,并考察其理化性质和在体外细胞上的摄取能力。方法采用复乳法制备Ova-NLC,以粒径、多分散指数(PDI)和Zeta电位为考察指标,采用单因素实验优化处方;用超滤法测定制剂的包封率和载药量;并考察Ova-NLC的体外释放和在DC2.4细胞上的摄取能力。结果 Ova-NLC的平均粒径为181.77±5.13 nm,PDI为0.15±0.03,Zeta电位为-22.3±0.62 mV。超滤法测得的包封率为86.54%±2.13%,载药量为18.03%±1.65%。体外释放72 h药物的累积释放量为85.77%±3.43%,在DC2.4细胞上无血无抗摄取1 h的摄取率为90.80%±4.72%。结论复乳法制备Ova-NLC的方法可行,体外具有一定的缓释作用且有较高的细胞摄取能力。
参考文献
[1]Nisbet AD,Saundry RH,Moir AJ,et al.The complete aminoacid sequence of hen ovalbumin[J].Eur J Biochem,1981,115:335-345.
[2]Bal SM,Hortensius S,Ding Z,et al.Co-encapsulation of antigen and toll-like receptor ligand in cationic liposomes affects the quality of the immune response in mice after intradermal vaccination[J].Vaccine,2011,29:1045-1052.
[3]Ma T,Wang L,Yang T,et al.Homogeneous PLGA-lipid nanoparticle as a promising oral vaccine delivery system for ovalbumin[J].Asian J Pharmac Sci,2014,9:129-136.
[4]Müller RH,Shegokar R,Keck CM.20 years of lipid nanoparticles(SLN and NLC):Present state of development and industrial applications[J].Cur Drug Discov Technol,2011,8:207-227.
[5]曹丰亮,郭晨煜,李其禄,等.纳米结构脂质载体的制备与应用研究进展[J].中国生化药物杂志,2012,33:93-96.
[6]BrugèF,Damiani E,Marcheggiani F,et al.A comparative study on the possible cytotoxic effects of different nanostructured lipid carrier(NLC)compositions in human dermal fibroblasts[J].Int J Pharmac,2015,495:879-885.
[7]Beloqui A,Solinís Má,Rodríguez-Gascón A,et al.Nanostructured lipid carriers:Promising drug delivery systems for future clinics[J].Nanomed Nanotech Bio Med,2015,12:143-161.
[8]Xie S,Wang S,Zhu L,et al.The effect of glycolic acid monomer ratio on the emulsifying activity of PLGA in preparation of protein-loaded SLN[J].Colloids Surf B Biointerfaces,2009,74:358-361.
【关闭】
